Appointment

Oxford Biomedica PLC
13 February 2001



OXFORD BIOMEDICA APPOINTS NON-EXECUTIVE DIRECTOR

Oxford, UK - 13 February 2001: Oxford BioMedica ('BioMedica') announced today
that Mr Raj Uppal has been appointed as a Non-Executive Director to the Board.

Mr Uppal is a Chartered Accountant and was Finance and Commercial Director of
Quadrant Healthcare plc until the acquisition of Quadrant by Elan Corporation
plc in December 2000. He joined Quadrant as Finance Director in May 1996. He
has been retained by Elan Pharmaceutical Technologies (the drug delivery
division of Elan) as Senior Vice President. Previously he has worked at Ferry
Pickering Group plc as Deputy Chief Executive.

Commenting on the announcement, Professor Alan Kingsman, Chief Executive of
Oxford BioMedica, said:

'We are delighted that Raj has joined the team at BioMedica. His experience in
a wide range of industries and business aspects, and particularly with
Quadrant Healthcare, should be very valuable to BioMedica as it expands its
operations and establishes itself further as a leading company in the sector.
With Raj coming on board, BioMedica now has a Board of nine people with
considerable expertise to manage the Company.'

-Ends-

 For further information, please contact:

Oxford BioMedica plc

Professor Alan Kingsman, Chief Executive

Tel: [phone]

City/Financial Enquiries

David Simonson/Melanie Toyne Sewell

Tel: [phone]

Merlin Financial

Scientific/Trade Press Enquiries

Chris Gardner, HCC De Facto Group

Tel: [phone]

Notes to Editors


 1. Oxford BioMedica plc

    Established in 1995, the Company specialises in the development and
    application of gene-based therapeutics and immunotherapeutics for the
    treatment of disease in the areas of Oncology, Neurobiology and Viral
    Infection and in Gene Discovery. Oxford BioMedica plc was floated on the
    Alternative Investment Market of the London Stock Exchange in December
    1996.

    Currently Oxford BioMedica has corporate collaborations with Aventis,
    AstraZeneca, IDM, Modex Therapeutics, Nycomed Amersham, Valentis, Virbac
    and Wyeth. BioMedica has two products in Phase I/II clinical trials.
    MetXia(R) is in clinical trials for late-stage breast cancer (BC1) and
    ovarian cancer (OC1) and TroVaxTM is in clinical trials for late-stage
    colorectal cancer.

 2. World Wide Web

This release is also available on the World Wide Web at http://
www.oxfordbiomedica.co.uk